...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Reproductive toxicology >A population-based case-control teratologic study of oral erythromycin treatment during pregnancy.
【24h】

A population-based case-control teratologic study of oral erythromycin treatment during pregnancy.

机译：妊娠期口服红霉素的基于病例的病例对照畸形研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of the study was to evaluate the human teratogenic potential of oral erythromycin treatment during pregnancy in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 172 (0.5%) had received erythromycin, while of 22,865 pregnant women who had newborns or fetuses with congenital abnormalities, 113 (0.5%) had been treated with erythromycin (crude OR with 95% Cl = 1.1, 0.9-1.4). The case-control pair analysis did not indicate a teratogenic potential of erythromycin during the second through third months of gestation, i.e., in the critical period for most major congenital abnormalities. The frequency of maternal erythromycin treatments during the second-third months of pregnancy was also not higher in different congenital abnormality groups compared with the rate of the total control group as referent. Thus, treatment with oral erythromycin during pregnancy did not present detectable teratogenic risk to the fetus.
机译：这项研究的目的是在基于人群的匈牙利先天性异常病例对照监测（1980-1996年）数据集中评估怀孕期间口服红霉素对人类的致畸潜力。在38151名没有先天性异常的新生儿的孕妇中（人口对照组），有172名（0.5％）接受了红霉素，而在22865名新生儿或胎儿先天性异常的孕妇中，有113名（0.5％）接受了红霉素治疗。红霉素（粗制OR或95％Cl = 1.1，0.9-1.4）。病例对照对分析未显示在妊娠的第二个月至第三个月，即在大多数主要先天性异常的关键时期，红霉素有致畸作用。与先天总对照组的发生率相比，不同的先天性异常组在孕期第三到三个月的产妇使用红霉素的频率也没有更高。因此，在怀孕期间口服红霉素治疗不会对胎儿造成可检测的致畸风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号